Targeted Oncology Drugs: The Growing Market for HDAC Inhibitor Therapies
Targeted oncology drugs have revolutionized cancer treatment, offering more precise and effective therapies with fewer side effects compared to traditional chemotherapy. Histone deacetylase (HDAC) inhibitors are a significant class of these targeted agents, working by modulating the epigenome to combat cancer. The market for targeted oncology drugs is expanding, driven by a rising...
0 Комментарии 0 Поделились 72 Просмотры 0 предпросмотр